order,search_terms,results1,exp rheumatoid arthritis/,1780832,"Rheumatoid Arthritis/dt, dm, co, th, dr",344743,1 or 2,1780834,exp abatacept/,66835,"(Belatacept or Nulojix or Orencia).ti,ab.",9086,exp adalimumab/,239727,"(Humira or D2E7 Antibody).ti,ab.",4378,exp anakinra/,2699,"(Urine Interleukin 1 Inhibitor or Antril or Kineret or Anakinra).ti,ab.",245210,exp certolizumab pegol/,446211,"(Cimzia or Cimzias).ti,ab.",5512,exp etanercept/,2546013,"(Enbrel or TNF Receptor Type II-IgG Fusion Protein or Recombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein).ti,ab.",46614,exp golimumab/,433515,"Simponi.ti,ab.",3716,exp infliximab/,3999017,"Remicade.ti,ab.",58518,exp rituximab/,5950019,"(Mabthera or Rituxan or Rituximab CD20 Antibody).ti,ab.",71320,exp tocilizumab/,686721,"(atlizumab or Actemra).ti,ab.",7022,exp tofacitinib/,191423,"(tasocitinib or tofacitinib citrate or Xeljanz).ti,ab.",7924,exp sarilumab/,18225,or/4-24,11910526,Clinical trial/,93107527,randomized controlled trial/,45702328,controlled clinical trial/,43630829,multicenter study/,15788930,Phase 3 clinical trial/,2842331,Phase 4 clinical trial/,256432,exp RANDOMIZATION/,7436533,single blind procedure/,2774534,double blind procedure/,13997035,crossover procedure/,5195336,PLACEBO/,30840937,randomi?ed controlled trial$.tw.,16102538,rct.tw.,2456639,(random$ adj2 allocat$).tw.,3424440,single blind$.tw.,1958841,double blind$.tw.,17958042,((treble or triple) adj blind$).tw.,71543,placebo$.tw.,25677644,Prospective study/,38522745,or/25-43,182445046,case study/,4801847,case report.tw.,34156748,Abstract report/ or letter/,102275249,Conference proceeding.pt.,050,Conference abstract.pt.,257774051,Editorial.pt.,53800452,Letter.pt.,97847053,Note.pt.,67752654,or/45-52,516874355,44 not 53,147212356,3 and 24 and 54,578957,limit 55 to english language,5443